Global Psychedelic therapeutics market is estimated to be worth over USD 6.5 billion in 2030, predicts Roots Analysis

 A growing body of evidence suggests that using psychedelics, such as psilocybin and LSD, in combination with psychotherapy, can treat the symptoms of several mental health conditions, including depression and substance use disorders

 

Roots Analysis has announced the addition of “Global Psychedelic Therapeutics Market, 2020-2030” report to its list of offerings.

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of drug developers engaged in the development of psychedelic therapeutics. 

§  Tabulated profiles of prominent psychedelic therapeutics developers. shortlisted on the basis of the number of pipeline products).

§  Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis having two or more psychedelics-based therapies in phase II clinical studies and above).

§  An insightful analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics.

§  A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

§  A detailed analysis of nearly 545 grants that have been awarded to research institutes engaged in psychedelic therapeutics projects, in the period between 2015 and 2020 (till May).

§  An analysis of the partnerships that have been established in the recent past (2017-2020 till May),

§  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2017-2020.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Target Disease Indication

§  Anxiety and Depression

§  Trauma

§  Pain Disorder

§  Sleep related Disorder

§  Origin of Psychedelic Substance

§  Natural

§  Synthetic

§  Type of Psychedelic Substance

§  Gamma-hydroxybutyrate

§  Ketamine

§  MDMA

§  Psilocybin

§  Route of Administration

§  Oral

§  Intranasal

§  Sublingual

§  Key Geographies

§  North America

§  Europe

§  Asia-Pacific

Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Andrew Chadeayne (Founder & Chief Executive Officer, CaaMTech)

§  Janakan Krishnarajah (Chief Operating Officer and Chief Medical Officer, iX Biopharma)

§  Alexander Speiser (Chief Operating Officer, Orthogonal Thinker)

§  Tracy Cheung, (Chief Communications Officer, COMPASS Pathways)

Key companies covered in the report 

§  Celon Pharma

§  iX Biopharma

§  MAPS Public Benefit

§  MindMed

§  Janssen Pharmaceuticals

§  Jazz Pharmaceutical

 

For additional details, please visit 
https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles: 

1.     Endocannabinoid System Targeted Therapeutics Market, 2020-2030

2.     Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019

3.     Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

4.       Neoantigen Targeted Therapies Market, 2019-2030

5.       Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more